[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567761":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":50,"collaborators":26,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":26,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":26,"enrollmentInfo":61,"targetDuration":26,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":26,"overallStatus":70,"whyStopped":26,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Hansoh BioMedical R&D Company","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HS-10374","EXPERIMENTAL","Subjects will receive HS-10374 from Week 0 through Week 52.",[13],"Drug: HS-10374 6mg tablets",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Subjects will receive HS-10374 matching placebo from Week 0 through Week 16, and HS-10374 from Week 16 through Week 52.",[13,19],"Drug: HS-10374-matched placebo tablets",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","HS-10374 6mg tablets","Specified dose of HS-10374 tablets administered orally QD on specified days",[9,15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"HS-10374-matched placebo tablets","Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Jinhua Xu, MD","CONTACT","(+86)13818978539","xjhhsyy@163.com",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":26},"Huashan Hospital affiliated to Fudan University","Shanghai","Shanghai Municipality","China","CN",{"type":45,"coordinates":46},"Point",[47,48],121.45806,31.22222,{"lat":48,"lon":47},{"type":51,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100567761","phase-3-a-study-to-confirm-efficacy-and-safety-of-hs-10374-for-moderate-to-severe-plaque-psoriasis-100567761",false,"NCT06672393","A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis","A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female subjects aged 18 years and older\n* Diagnosis of plaque psoriasis for at least 6 months\n* Eligible for phototherapy or systemic therapy\n* Plaque covering ≥ 10% of BSA\n* PASI ≥ 12, sPGA ≥3\n\nExclusion Criteria:\n\n* Diagnosis of non-plaque psoriasis or drug-induced psoriasis\n* Recent history of infection, history or risk of serious infection\n* Any major illness or evidence of unstable condition of major organ systems including psychiatric disease\n* Any condition possibly affecting the PK process of the study drug\n* Evidence of other skin conditions that would interfere with the evaluation of psoriasis\n* History of hypersensitivity to the ingredients of study drugs, history of anaphylaxis\n* Prior exposure to TYK2 inhibitors\n* Have received the prohibited treatment during the protocol required washout period\n* Any significant laboratory or procedure abnormalities that might place the subject at unacceptable risk during this study period","ALL","18 Years",{"count":62,"type":63},375,"ESTIMATED","INTERVENTIONAL",[66],"PHASE3","This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.",[69],"Psoriasis","NOT_YET_RECRUITING","2024-10-31",{"date":73,"type":74},"2024-11-04","ACTUAL",{"date":73,"type":63},{"date":77,"type":63},"2026-06-29",{"name":5,"class":6},1]